
A particular group of patients have proven to benefit from being treated with Lundbeck's Trintellix/Brintellix – a group which has otherwise had difficulty finding treatment, according to a Lundbeck press release.
The study contained 100 patients with a primary diagnosis of major depressive disorder (MDD) and a comorbid diagnosis of generalized anxiety disorder (GAD).
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app